- Home
- BGI vs IGC Comparison
BGI vs IGC Comparison
Compare BGI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- IGC
- Stock Information
- Founded
- BGI 1879
- IGC 2005
- Country
- BGI Canada
- IGC United States
- Employees
- BGI N/A
- IGC N/A
- Industry
- BGI
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- IGC Health Care
- Exchange
- BGI Nasdaq
- IGC Nasdaq
- Market Cap
- BGI 17.8M
- IGC 20.2M
- IPO Year
- BGI 2005
- IGC N/A
- Fundamental
- Price
- BGI $0.86
- IGC $0.36
- Analyst Decision
- BGI
- IGC Strong Buy
- Analyst Count
- BGI 0
- IGC 2
- Target Price
- BGI N/A
- IGC $3.88
- AVG Volume (30 Days)
- BGI 98.5K
- IGC 7.2M
- Earning Date
- BGI 07-29-2025
- IGC 08-07-2025
- Dividend Yield
- BGI N/A
- IGC N/A
- EPS Growth
- BGI N/A
- IGC N/A
- EPS
- BGI N/A
- IGC N/A
- Revenue
- BGI $131,596,265.00
- IGC $1,271,000.00
- Revenue This Year
- BGI N/A
- IGC $15.26
- Revenue Next Year
- BGI N/A
- IGC $3.41
- P/E Ratio
- BGI N/A
- IGC N/A
- Revenue Growth
- BGI 4.01
- IGC N/A
- 52 Week Low
- BGI $0.76
- IGC $0.25
- 52 Week High
- BGI $2.95
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- BGI 44.88
- IGC 55.26
- Support Level
- BGI $0.77
- IGC $0.30
- Resistance Level
- BGI $0.98
- IGC $0.36
- Average True Range (ATR)
- BGI 0.06
- IGC 0.03
- MACD
- BGI -0.01
- IGC 0.00
- Stochastic Oscillator
- BGI 47.43
- IGC 31.06
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.